Disease relevance of Shogaol

• U937 cells were differentiated and exposed to lipopolysaccharide (LPS) from Escherichia coli (1mug/ml) in the presence or absence of organic extracts or standard compounds found in ginger (6-, 8-, 10-gingerol or 6-shogaol) for 24h [1].

High impact information on Shogaol

• Moreover, shogaol-mediated neuroprotection has been linked with shogaol's attenuation of p38 mitogen-activated protein kinase, p-SAPK/JNK and signal transducer, and with transcription-3 activation [2].
• 6-Shogaol, a natural product, reduces cell death and restores motor function in rat spinal cord injury [2].
• The shogaol-treated group recovered hindlimb reflexes more rapidly and a higher percentage of these rats regained responses compared with the untreated injured rats [2].
• Shogaol attenuated apoptotic cell death, including poly(ADP-ribose) polymerase activity, and reduced astrogliosis and hypomyelination which occurs in areas of active cell death in the spinal cords of SCI rats [2].
• In this study, we determined the variation in 6-gingerol, 6-shogaol, 8-gingerol, and 10-gingerol concentrations and labeling of different brands of ginger root dietary supplements [3].

Biological context of Shogaol

• The foremost protective effect of shogaol in SCI would therefore be manifested in the suppression of the acute secondary apoptotic cell death [2].
• It was found that gingerol exhibited novel reversible kinetics, in which it undergoes dehydration-hydration transformations with shogaol, the major degradation product [4].
• It was observed that ginger extract, gingerol and shogaol were mutagenic on metabolic activation in strains TA 100 and TA 1535, but zingerone was non-mutagenic in all the four strains with or without S9 mix [5].
• (6)-Shogaol-induced pressor responses in blood pressure of rats were studied [6].

Anatomical context of Shogaol

• Our data show that the therapeutic outcome of shogaol probably results from its comprehensive effects of blocking apoptotic cell death, resulting in the protection of white matter, oligodendrocytes and neurons, and inhibiting astrogliosis [2].
• In addition, 6-shogaol ameliorated BaCl(2) -induced hyperperistalsis of the small intestine in vivo [7].
• CONCLUSION: From these results, it is concluded that 6-shogaol reduced the inflammatory response and protected the femoral cartilage from damage produced in a CFA monoarthritic model of the knee joint of rats [8].
• The effect of 6-shogaol compared to the controls was associated with significantly lower concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) in the blood and infiltration of leukocytes, including lymphocytes and monocytes/macrophages, into the synovial cavity of the knee [8].

Associations of Shogaol with other chemical compounds

• RESULTS: The 6-gingerol concentration of the ginger powder dietary supplements ranged from 0.0 to 9.43 mg/g, (mean +/- standard deviation, 2.56 +/- 2.95 mg/g), 6-shogaol ranged from 0.16 to 2.18 mg/g (1.27 +/- 0.58), 8-gingerol ranged from 0.00 to 1.1 mg/g (0.47 +/- 0.34), and 10-gingerol ranged from 0.00 to 1.40 mg/g (0.36 +/- 0.51) [3].
• In the cardiovascular system, both (6)-shogaol and (6)-gingerol produced depressor response at lower doses on the blood pressure [9].
• The rapid fall, which followed immediately after injection of (6)-shogaol, disappeared with the use of atropine and vagotomy [10].
• Pressor response induced by the injection of (6)-shogaol (10 micrograms) into the perfusion circuit was not affected by phentolamine and spinal destruction [6].
• In the gastro-intestinal system, (6)-shogaol intensively inhibited the traverse of charcoal meal through the intestine in contrast with (6)-gingerol after i.v. administration of 3.5 mg/kg, but (6)-shogaol facilitated such an intestinal function after oral administration of 35 mg/kg [9].

Analytical, diagnostic and therapeutic context of Shogaol

• The effect of (6)-shogaol (100 microM) was attenuated in slices from rats with dorsal rhizotomy and abolished by elimination of calcium ions from the perfusion medium [11].
• Our finding that the administration of shogaol prevents secondary pathological events in traumatic SCIs and promotes recovery of motor functions in an animal model raises the issue of whether shogaol could be used therapeutically in humans after SCI [2].
• The 6-gingerol, 6-shogaol, 8-gingerol, and 10-gingerol concentrations of the dietary supplements were determined by high-performance liquid-chromatography [3].
• Intraventricular injection of (6)-shogaol (0.1 to 0.5 microgram) caused a pressor response in a dose-dependent manner [6].

References